Foster G R, Goldin R D, Hay A, McGarvey M J, Stark G R, Thomas H C
Imperial Cancer Research Fund, London, United Kingdom.
Hepatology. 1993 May;17(5):757-62.
The terminal protein domain of the hepatitis B viral polymerase can inhibit the cellular response to interferon. To clarify the clinical relevance of this inhibitory effect, we examined the expression of terminal protein in liver biopsy specimens from patients with chronic hepatitis B infection. We found that expression of terminal protein is associated with a failure of hepatocytes to respond to interferon, as assessed by expression of the interferon-inducible protein beta 2-microglobulin. Patients whose liver specimens contained large numbers of cells expressing terminal protein tended not to respond to treatment. During interferon therapy the percentage of cells expressing terminal protein remained constant, but treatment significantly reduced the number of cells that expressed the hepatitis B nucleocapsid protein. Hence expression of terminal protein in a cell may prevent elimination of the virus by interferon therapy.
乙肝病毒聚合酶的末端蛋白结构域可抑制细胞对干扰素的反应。为阐明这种抑制作用的临床相关性,我们检测了慢性乙肝感染患者肝活检标本中末端蛋白的表达。我们发现,通过干扰素诱导蛋白β2-微球蛋白的表达评估,末端蛋白的表达与肝细胞对干扰素无反应相关。肝标本中含有大量表达末端蛋白细胞的患者往往对治疗无反应。在干扰素治疗期间,表达末端蛋白的细胞百分比保持不变,但治疗显著减少了表达乙肝核衣壳蛋白的细胞数量。因此,细胞中末端蛋白的表达可能会阻碍干扰素疗法清除病毒。